Saturday, 31 October 2026European Markets

FDJ And 2 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - fdj (fdj.pa), rubis (rui.pa), ald (ald.pa) are the highest payout ratio stocks on this list.

here's the data we've collected of stocks with a high payout ratio at the moment. the payout ratio in itself isn't a guarantee of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

when researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. fdj (fdj.pa)

61.43% payout ratio

la française des jeux société anonyme engages in the gaming operation and distribution business in france and internationally. it offers lottery games, such as draw and instant games at points of sale and online; sports betting at points of sale; online poker; online horse-race and sports betting; betting and risk management services to sports betting operators; digital gaming platform; and s sports betting technology, as well as holds and administers draws for participating lotteries. the company was founded in 1933 and is headquartered in boulogne-billancourt, france.

earnings per share

as for profitability, fdj has a trailing twelve months eps of €2.23.

pe ratio

fdj has a trailing twelve months price to earnings ratio of 16.94. meaning, the purchaser of the share is investing €16.94 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 42.59%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 3, 2024, the estimated forward annual dividend rate is 1.78 and the estimated forward annual dividend yield is 5.06%.

moving average

fdj's value is under its 50-day moving average of €37.81 and way above its 200-day moving average of €34.24.

volume

today's last reported volume for fdj is 149175 which is 19.76% below its average volume of 185922.

revenue growth

year-on-year quarterly revenue growth grew by 6.7%, now sitting on 2.62b for the twelve trailing months.

more news about fdj.

2. rubis (rui.pa)

56.14% payout ratio

rubis engages in the operation of bulk liquid storage facilities for commercial and industrial customers in europe, africa, and the caribbean. the company operates through energy distribution and renewable electricity production segments. it is involved in the bulk liquid storage of fuels, biofuels, chemicals, and agrifood products; and retails and distributes fuels, heating oils, lubricants, liquefied gases, and bitumen, as well as provides logistics services comprising trading-supply, refining, and shipping activities. the company also engages in the production of photovoltaic electricity; provision of car wash services; and operation of convenience stores and quick-service restaurants across various service stations operated under the rubis and vito brands. it serves transportation, infrastructure, hotel, aviation, marine, and public works sectors. rubis was incorporated in 1954 and is headquartered in paris, france.

earnings per share

as for profitability, rubis has a trailing twelve months eps of €3.42.

pe ratio

rubis has a trailing twelve months price to earnings ratio of 9.57. meaning, the purchaser of the share is investing €9.57 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.05%.

more news about rubis.

3. ald (ald.pa)

45.49% payout ratio

ald s.a. provides service leasing and vehicle fleet management services. its products and services include full service leasing, fleet management, outsourcing solutions, and sale and lease back; fleet consultancy; and tools and services for fleet managers and drivers. the company is also involved in trading used cars and light commercial vehicles, and the retail sale of vehicles. the company operates in western europe, central and eastern europe, northern europe, south america, africa, and asia. ald s.a. was incorporated in 1998 and is based in rueil-malmaison, france. ald s.a. operates as a subsidiary of société générale société anonyme.

earnings per share

as for profitability, ald has a trailing twelve months eps of €1.17.

pe ratio

ald has a trailing twelve months price to earnings ratio of 5.19. meaning, the purchaser of the share is investing €5.19 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14%.

revenue growth

year-on-year quarterly revenue growth grew by 755.9%, now sitting on 15.56b for the twelve trailing months.

more news about ald.

1. 1 (1)

1% payout ratio

1

earnings per share

as for profitability, 1 has a trailing twelve months eps of €1.

pe ratio

1 has a trailing twelve months price to earnings ratio of 1. meaning, the purchaser of the share is investing €1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

more news about 1.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com